Brokerages Set Gain Therapeutics, Inc. (NASDAQ:GANX) Target Price at $7.50

Gain Therapeutics, Inc. (NASDAQ:GANX) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.50.

Several equities research analysts have issued reports on GANX shares. Roth Capital reaffirmed a “buy” rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Oppenheimer reissued an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th. BTIG Research reissued a “buy” rating and issued a $5.00 price target on shares of Gain Therapeutics in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, June 21st. Finally, Weiss Ratings cut shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th.

Gain Therapeutics Price Performance

Shares of Gain Therapeutics stock opened at $2.07 on Friday. The business has a 50 day simple moving average of $1.83 and a two-hundred day simple moving average of $1.93. Gain Therapeutics has a 12 month low of $1.53 and a 12 month high of $4.34. The stock has a market capitalization of $90.33 million, a P/E ratio of -4.14 and a beta of 0.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. As a group, analysts predict that Gain Therapeutics will post -0.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Gain Therapeutics

A number of large investors have recently made changes to their positions in the stock. Apollon Wealth Management LLC lifted its position in Gain Therapeutics by 33.7% during the first quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after buying an additional 6,675 shares in the last quarter. Geode Capital Management LLC grew its holdings in Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after buying an additional 8,251 shares in the last quarter. Sprott Inc. acquired a new stake in shares of Gain Therapeutics in the 4th quarter worth $39,000. Commonwealth Equity Services LLC acquired a new stake in shares of Gain Therapeutics in the 4th quarter worth $41,000. Finally, Millennium Management LLC acquired a new stake in shares of Gain Therapeutics in the 4th quarter worth $45,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.